Purple Biotech Ltd (TLV: PPBT)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
4.800
-0.100 (-2.04%)
Nov 19, 2024, 12:13 PM IDT
-87.85%
Market Cap 17.20M
Revenue (ttm) n/a
Net Income (ttm) -43.34M
Shares Out 365.87M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,100
Open 4.900
Previous Close 4.900
Day's Range 4.800 - 4.900
52-Week Range 4.800 - 40.400
Beta 0.29
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin recept... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Gil Efron
Employees 20
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol PPBT
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.